Each film coated tablets contains:
Cefuroxime Axteil IP 250 mg
Cefuroxime Axteil IP 500 mg
is a semisynthetic, broad-spectrum cephalosporin antibiotic for oral administration.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil and other antibacterial drugs, cefuroxime axetil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
Pharyngitis/Tonsillitis, Acute Bacterial Otitis Media, Urinary Tract Infections, Gonorrhea, Lyme Disease (erythema migrans).
Mechanism of Action
Cefuroxime, like the penicillins, is a beta-lactam antibiotic. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cefuroxime interferes with an autolysin inhibitor.
||37% on empty stomach, up to 52% if taken after food
||Urine 66-100% Unchanged
Cefuroxime is a β-lactam type antibiotic. More specifically, it is a second-generation cephalosporin. Cephalosporins work the same way as penicillins: they interfere with the peptidoglycan synthesis of the bacterial wall by inhibiting the final transpeptidation needed for the cross-links. This effect is bactericidal. Cefuroxime is effective against the following organisms: Aerobic Gram-positive Microorganisms: Staphylococcus aureus, Streptococcus pneumoniae,
Streptococcus pyogenes. Aerobic Gram-negative Microorganisms: Escherichia coli, Haemophilus influenzae (including beta-lactamase-producing strains), Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis (including beta-lactamase-producing strains), Neisseria gonorrhoeae (including beta-lactamase-producing strains). Spirochetes: Borrelia burgdorferi. Cefuroxime axetil is the prodrug.
It is absorbed from the gastrointestinal tract. Absorption is greater when taken after food (absolute bioavailability increases from 37% to 52%).
50% to serum protein.
The axetil moiety is metabolized to acetaldehyde and acetic acid.
Its half life is Approximately 80 minutes following intramuscular or intravenous injection.
Nausea, vomiting, diarrhea, strange taste in the mouth, or stomach pain may occur. Diaper rash may occur in young children. Dizziness and drowsiness may occur less frequently, especially with higher doses.